Barclays
IOVA icon

Barclays’s Iovance Biotherapeutics IOVA Stock Holding History

Barclays’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.64M Buy
+447,800
New +$3.2M ﹤0.01% 1888
2020
Q1 		– Sell
-4,000
Closed -$111K – 6292
2019
Q4 		$111K Buy
+4,000
New +$91K ﹤0.01% 5424

Other funds holding IOVA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
C WorldWide Group
C WorldWide Group Copenhagen, Denmark $3.96B AUM 10.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Barclays's IOVA Position: Q3 2026 in Review

Barclays increased its Iovance Biotherapeutics (IOVA) stake by 246% in Q3 2026, buying an estimated $2.67M and bringing the position to 523,545 shares worth $7.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

Barclays first reported a position in IOVA in Q2 2015 and has held it in 45 quarters since. 124 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Barclays held 523,545 shares of Iovance Biotherapeutics worth $7.76M as of Q3 2026.
  • Barclays bought 372,433 Iovance Biotherapeutics shares in Q3 2026, an estimated $2.67M.
  • Iovance Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1799 holding.
  • Barclays first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 45 quarters since.
  • 124 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.